InvestSMART

Control Bionics Limited (ASX:CBL)

ALERT: Price-sensitive ASX Announcement for CBL
Current share price for CBL : $0.090 0.056 (164.71%)+
Announcement
Release
31 Oct 2025 8:14AM
Price at Release
$0.034
Full Release
download
Summary
Control Bionics Limited reported its quarterly activities and cash flow for the quarter ended 30 September 2025. The company made significant strides in expanding its NeuroNode distribution in the US and globally, with reimbursement coverage now reaching over 70% of the US population. The NeuroStrip technology gained traction in sports performance and rehabilitation sectors. Financially, the company recorded a cash receipt of $1.68 million, a 24% increase from the previous quarter, and conducted a successful capital raise of $1.5 million. Operational highlights included the initiation of scale manufacturing of NeuroStrip devices and a promising sales pipeline, especially in Australia with revenue growth of 27% over the previous year. Strategic focuses for 2026 include achieving profitability, expanding NeuroNode sales, broadening NeuroStrip's market reach, accelerating growth through partnerships, and building a high-performance organization.
Key Points
  • NeuroNode distribution strategy advancing in US and globally.
  • US reimbursement coverage exceeds 70% of the population.
  • NeuroStrip technology gaining momentum in sports performance and rehabilitation.
  • Cash receipts totalled $1.68 million, a 24% increase over the last quarter.
  • Successful capital raise of $1.5 million.
  • Revenue in Australia grew by 27% compared to the previous year.
  • Focus on achieving profitability and expanding product sales in core markets.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.